James Robinson, CEO of Alkermes Inc. plc, has a solid background in pharmaceuticals with a BS degree in marketing from DePaul University. After joining Alkermes in March 2018, he transitioned from his role as President, Americas Operations at Astellas US...

James Robinson, CEO of Alkermes Inc. plc, has a solid background in pharmaceuticals with a BS degree in marketing from DePaul University. After joining Alkermes in March 2018, he transitioned from his role as President, Americas Operations at Astellas US LLC, where he led a team of around 2,000 employees. His career has included significant responsibilities in sales, marketing, and organizational development in the healthcare sector. Under Robinson's leadership, Alkermes has seen important approvals and advancements in its drug pipeline, focusing on treatments for severe mental illnesses and addiction. In 2023, he received a total compensation of $6.1 million, which reflects well on his ability to drive company performance. Interestingly, Robinson has played key roles in engaging with policymakers to improve treatment accessibility and successfully launched new product initiatives.